JANUX THERAPEUTICS INC's ticker is JANX and the CUSIP is 47103J105. A total of 66 filers reported holding JANUX THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is 0.13 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $18,495,608 | -83.2% | 441,528 | -84.9% | 0.52% | -82.9% |
| Q1 2024 | $109,931,148 | +123.7% | 2,919,818 | -36.2% | 3.02% | +145.7% |
| Q4 2023 | $49,141,447 | +6.4% | 4,579,818 | 0.0% | 1.23% | -1.2% |
| Q3 2023 | $46,164,565 | -5.3% | 4,579,818 | +11.5% | 1.24% | -8.4% |
| Q2 2023 | $48,749,437 | +154.1% | 4,106,945 | +159.0% | 1.36% | +93.9% |
| Q1 2023 | $19,186,692 | -0.9% | 1,585,677 | +7.8% | 0.70% | -14.2% |
| Q4 2022 | $19,364,299 | -2.7% | 1,470,334 | 0.0% | 0.82% | -0.6% |
| Q3 2022 | $19,908,000 | +10.9% | 1,470,334 | 0.0% | 0.82% | -5.2% |
| Q2 2022 | $17,953,000 | +9.6% | 1,470,334 | +28.7% | 0.87% | +32.4% |
| Q1 2022 | $16,381,000 | -18.4% | 1,142,340 | +12.3% | 0.66% | -10.2% |
| Q4 2021 | $20,072,000 | -8.8% | 1,017,314 | 0.0% | 0.73% | -15.1% |
| Q3 2021 | $22,005,000 | -25.0% | 1,017,314 | -13.5% | 0.86% | -21.9% |
| Q2 2021 | $29,358,000 | – | 1,176,681 | – | 1.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 9,165,652 | $383,949,162 | 5.08% |
| Logos Global Management LP | 750,000 | $31,417,500 | 2.55% |
| Cormorant Asset Management, LP | 1,050,000 | $43,984,500 | 2.54% |
| Paradigm Biocapital Advisors LP | 1,564,452 | $65,534,894 | 2.51% |
| Orbimed Advisors | 2,979,828 | $124,824,995 | 2.46% |
| Vestal Point Capital, LP | 725,000 | $30,370,250 | 2.26% |
| EcoR1 Capital, LLC | 1,469,818 | $61,570,676 | 1.88% |
| Avidity Partners Management LP | 840,219 | $35,196,774 | 1.50% |
| Ratan Capital Management LP | 105,757 | $4,430,160 | 1.34% |
| STEMPOINT CAPITAL LP | 92,949 | $3,893,634 | 1.14% |